The benefits of abciximab questioned in percutaneous coronary interventions following pretreatment with high-dose clopidogrel.
Salam
Amar M
AM
Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, P.O.Box 3050, Doha, Qatar. amaramin@yahoo.com
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077144:Clopidogrel; D013988:Ticlopidine; D000077284:Abciximab